Skip to Content

Angela Brand

Angela Brand

Prof. Angela Brand, MD PhD MPH is Founding Director and Full Professor of the Institute for Public Health Genomics (IPHG) at the Faculty of Health, Medicine and Life Sciences at Maastricht University, the Netherlands, as well as Adjunct Professor at the Manipal Life Sciences Centre of Manipal University, India. She is Paediatrician and Specialist in Public Health Medicine, holds a PhD in pathology (Münster University, Germany) and a Master of Public Health from Johns Hopkins University, USA.

She received her habilitation in Public Health Genomics focussing on Health Technology Assessment (Bremen University, Germany) being in Europe the first HTA on genomics. She is Director of the European Centre for Public Health Genomics (ECPHG), which has a formal collaboration agreement with the EC-JRC IPTS in Sevilla and collaborates with Public Health Genomics related institutions and organizations all over the world such as the CDC Atlanta, the Public Health Agency Canada or the BGI China. She is Coordinator of the Public Health Genomics European Network (PHGEN,, Full Partner of the EU Flagship Pilot Project IT Future of Medicine (ITFoM,, President of the Section Public Health Genomics within the European Public Health Association (EUPHA), Edtor-in-Chief of the international journal Public Health Genomics, Excecutive Director of the Public Health Genomics international network GRaPH-Int, Associated Member of the international consortium Public Population Project in Genomics (P3G) on biobanking, Advisory Board Member of the EU Innovation Medicine Initiative (IMI) project OncoTrack (, Steering Committee Member of the “Forward Look on Personalized Medicine” of the European Science Foundation, and Scientific Consultation Group Member of the European Centre for Disease Prevention and Control (ECDC).

She serves as Expert for the European Agency for Reconstruction, the OECD, WHO, the European Commission, the Netherlands Genomics Initiative (NGI), the German Robert Koch-Institut (RKI), Genome Canada, the European Science Foundation among others. She collaborates for several years also with industry partners mainly in the field of Pharmacogenomics such as with Roche, Pfizer, Novartis, MSD or Bayer-Schering and produced for them also HTA reports on health innovations. She is Fellow of the Rockefeller Foundation, USA, and of the 21st Century Trust of the Wellcome Trust, UK.

Selected publications:

1. Brand A. Public Health Genomics and Personalized Healthcare: a pipeline from cell to society. Drug Metab Drug Interact 2012; 27(3): 121–123

2. Brand A, Lal JA for the Public Health Genomics European Network (PHGEN II). European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome based Information and Technologies: the 2012 Declaration of Rome. Drug Metab Drug Interact 2012; 27(3): 177–182

3. Cesuroglu T, van Ommen B, Malats N., Sudbrak R, Lehrach H, Brand A. Public health perspective: from personalized medicine to personal health. Personalized Medicine 2012; 9(2): 115-119.

4. Harvey A, Brand A, Holgate ST, Kristiansen LV, Lehrach H, Palotie A, Prainsack B. The future of technologies for personalised medicine. New Biotechnology

5. Lal JA, Schulte in den Bäumen T, Morre SA, Brand A. Public health and valorization of genome-based technologies: a new model. Journal of Translational Medicine 2011; 9(207).

6. Becla L, Lunshof JE, Gurwitz D, Schulte in den Bäumen T, Westerhoff HV, Lange BM, Brand A: Health technology assessment in the era of personalized health care. International Journal of Technology Assessment in Health Care 2011; 27:118-126.

7. Brand A. Public health genomics – public health goes personalized? Eur J Public Health 2011; 21(1): 2–3.

8. Rosenkötter N, Vondeling H, Blancquaert I, Mekel OC, Kristensen FB, Brand A. The contribution of health technology assessment, health needs assessment, and health impact assessment to the assessment and translation of technologies in the field of public health genomics. Public Health Genomics 2011; 14(1): 43-52.